How I treat adverse effects of CAR-T cell therapy

被引：32
作者：
Yanez, Lucrecia [1 ,2 ]
Alarcon, Ana [3 ]
Sanchez-Escamilla, Miriam [1 ]
Perales, Miguel-Angel [3 ,4 ]
机构：
[1] Hosp Univ Marques Valdecilla, Hematol, Santander, Cantabria, Spain
[2] Univ Cantabria, Med & Psychiat Dept, Santander, Cantabria, Spain
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA
[4] Weill Cornell Med Coll, New York, NY USA
来源：
ESMO OPEN | 2019年 / 4卷
关键词：
CAR-T cells; cellular therapy; chimeric antigen receptor; cytokine release syndrome; immune effector cell-associated neurotoxicity syndrome;
D O I：
10.1136/esmoopen-2020-000746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chimeric antigenreceptor (CAR) T cell therapy has demonstrated efficacy in B cell malignancies, particularly for acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphomas. However, this regimen is not harmless and, in some patients, can lead to a multi organ failure. For this reason, the knowledge and the early recognition and management of the side effects related to CAR-T cell therapy for the staff is mandatory. In this review, we have summarised the current recommendations for the identification, gradation and management of the cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as infections, and related to CAR-T cell therapy.
引用
收藏
页数：5
相关论文
共 18 条
  • [1] [Anonymous], 2019, J CLIN ONCOL S
  • [2] Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
    Brudno, Jennifer N.
    Kochenderfer, James N.
    [J]. BLOOD REVIEWS, 2019, 34 : 45 - 55
  • [3] Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
    Cordeiro, Ana
    Bezerra, Evandro D.
    Hirayama, Alexandre V.
    Hill, Joshua A.
    Wu, Qian V.
    Voutsinas, Jenna
    Sorror, Mohamed L.
    Turtle, Cameron J.
    Maloney, David G.
    Bar, Merav
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (01) : 26 - 33
  • [4] Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
    Frey, Noelle, V
    Shaw, Pamela A.
    Hexner, Elizabeth O.
    Pequignot, Edward
    Gill, Saar
    Luger, Selina M.
    Mangan, James K.
    Loren, Alison W.
    Perl, Alexander E.
    Maude, Shannon L.
    Grupp, Stephan A.
    Shah, Nirav N.
    Gilmore, Joan
    Lacey, Simon F.
    Melenhorst, Jos J.
    Levine, Bruce L.
    June, Carl H.
    Porter, David L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05) : 415 - 422
  • [5] Early and late hematologic toxicity following CD19 CAR-T cells
    Fried, Shalev
    Avigdor, Abraham
    Bielorai, Bella
    Meir, Amilia
    Besser, Michal J.
    Schachter, Jacob
    Shimoni, Avichai
    Nagler, Arnon
    Toren, Amos
    Jacoby, Elad
    [J]. BONE MARROW TRANSPLANTATION, 2019, 54 (10) : 1643 - 1650
  • [6] Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy
    Hill, Joshua A.
    Krantz, Elizabeth M.
    Hay, Kevin A.
    Dasgupta, Sayan
    Stevens-Ayers, Terry
    Bender Ignacio, Rachel A.
    Bar, Merav
    Maalouf, Joyce
    Cherian, Sindhu
    Chen, Xueyan
    Pepper, Greg
    Riddell, Stanley R.
    Maloney, David G.
    Boeckh, Michael J.
    Turtle, Cameron J.
    [J]. BLOOD ADVANCES, 2019, 3 (22) : 3590 - 3601
  • [7] CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy
    Hill, Joshua A.
    Giralt, Sergio
    Torgerson, Troy R.
    Lazarus, Hillard M.
    [J]. BLOOD REVIEWS, 2019, 38
  • [8] Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy
    Hill, Joshua A.
    Li, Daniel
    Hay, Kevin A.
    Green, Margaret L.
    Cherian, Sindhu
    Chen, Xueyan
    Riddell, Stanley R.
    Maloney, David G.
    Boeckh, Michael
    Turtle, Cameron J.
    [J]. BLOOD, 2018, 131 (01) : 121 - 130
  • [9] Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
    Jain, Tania
    Bar, Merav
    Kansagra, Ankit J.
    Chong, Elise A.
    Hashmi, Shahrukh K.
    Neelapu, Sattva S.
    Byrne, Michael
    Jacoby, Elad
    Lazaryan, Aleksandr
    Jacobson, Caron A.
    Ansell, Stephen M.
    Awan, Farrukh T.
    Burns, Linda
    Bachanova, Veronika
    Bollard, Catherine M.
    Carpenter, Paul A.
    DiPersio, John F.
    Hamadani, Mehdi
    Heslop, Helen E.
    Hill, Joshua A.
    Komanduri, Krishna, V
    Kovitz, Craig A.
    Lazarus, Hillard M.
    Serrette, Justin M.
    Mohty, Mohamad
    Miklos, David
    Nagler, Arnon
    Pavletic, Steven Z.
    Savani, Bipin N.
    Schuster, Stephen J.
    Kharfan-Dabaja, Mohamed A.
    Perales, Miguel-Angel
    Lin, Yi
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (12) : 2305 - 2321
  • [10] ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
    Lee, Daniel W.
    Santomasso, Bianca D.
    Locke, Frederick L.
    Ghobadi, Armin
    Turtle, Cameron J.
    Brudno, Jennifer N.
    Maus, Marcela, V
    Park, Jae H.
    Mead, Elena
    Pavletic, Steven
    Go, William Y.
    Eldjerou, Lamis
    Gardner, Rebecca A.
    Frey, Noelle
    Curran, Kevin J.
    Peggs, Karl
    Pasquini, Marcelo
    DiPersio, John F.
    van den Brink, Marcel R. M.
    Komanduri, Krishna, V
    Grupp, Stephan A.
    Neelapu, Sattva S.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (04) : 625 - 638
12